Health stocks were propped up on Wednesday by earnings and revenue guidance, regulatory actions and general plans for 2008.Barr Pharmaceuticals ( BRL) said on Wednesday that it's asking the FDA to approve the generic version of Eloxatin, an injectible colon cancer treatment. In doing so, the company is challenging Sanofi-Aventis' ( SNY) patent. Sanofi and partner Debiopharm filed a lawsuit on Friday to prevent Barr from moving the generic drug forward. The product had sales of approximately $1.1 billion in the U.S., based on IMS sales data for the 12 months ended October 2007. Barr was trading up $1.85, or 3.6%, at $53.68. Other stocks rose on bullish outlooks. Contract research organization Pharmaceutical Product Development ( PPDI) rose $4.15, or 9.8%, to $46.65 after the company predicted Tuesday post-close that its 2008 profit will beat Wall Street expectations. The company said it expects 2008 profits to be between $1.82 and $1.92 a share, and anticipates revenue between $1.54 billion and $1.59 billion vs. prior guidance of $1.29 billion to $1.34 billion. The Thomson Financial consensus target was $1.71 a share on revenue of $1.51 billion. Similarly, ViroPharma ( VPHM) said Wednesday that it expected sales for its lead product Vanconcin, a treatment for gastrointestinal tract infections, to reach $210 million to $235 million in 2008, vs. prior-year sales of $200 million to $208 million in 2007. Analysts are looking for sales of $205.3 million in 2007 and $180.3 million in 2008.